Leerink assumed coverage of Mind Medicine with an Outperform rating and $20 price target The firm likes the emerging psychedelics space with increasing investment in clinical development across multiple psychiatric indications, clear FDA guidance, and more established commercial infrastructure following the launch of J&J’s Spravato. The firm also believes MM120 has a good chance of working based on published data.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNMD: